SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

Home・Lista de Ações・Nanobiotix

N
Nanobiotix

Fechado

36.8 -4.37

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

35.38

Máximo

38.48

Indicadores-chave
By Trading Economics
Rendimento	-13M -19M
Vendas	-24M 3M
Margem de lucro	-618.236
Funcionários	100
EBITDA	-14M -13M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+55.93% upside

Dividendos
By Dow Jones
Próximos Ganhos	27 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	592M 1.9B
Abertura anterior	41.17
Fecho anterior	36.8

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

2.975 / 3.015 Suporte e Resistência

Nanobiotix Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de mai. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 de mai. de 2026, 22:52 UTC

Grandes Movimentos do Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 de mai. de 2026, 23:44 UTC

Ganhos

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 de mai. de 2026, 23:35 UTC

Conversa de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 de mai. de 2026, 23:15 UTC

Conversa de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 de mai. de 2026, 23:14 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 de mai. de 2026, 23:02 UTC

Conversa de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 22:27 UTC

Conversa de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 de mai. de 2026, 22:14 UTC

Conversa de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 de mai. de 2026, 22:10 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 de mai. de 2026, 22:00 UTC

Ganhos

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 de mai. de 2026, 21:38 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 de mai. de 2026, 21:27 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 de mai. de 2026, 21:20 UTC

Ganhos

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 de mai. de 2026, 21:19 UTC

Ganhos

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 de mai. de 2026, 21:18 UTC

Ganhos

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 de mai. de 2026, 21:16 UTC

Ganhos

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparação entre Pares

Variação de preço

Nanobiotix Previsão

Preço-alvo

By TipRanks

55.93% parte superior

Previsão para 12 meses

Média 60 EUR 55.93%

Máximo 60 EUR

Mínimo 60 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Nanobiotix - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Nanobiotix - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

2.975 / 3.015Suporte e Resistência

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.